• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 51Southampton Health Technology Assessments Centre and the manufacturers' baseline cost-effectiveness results vs MP

ResultAnalysisMPMPTVMPCTDa
Total cost (£)SHTAC21,43932,59857,16829,983
Janssen–Cilag54,43459,32266,67656,668
Celgene136521,13342,616
Total QALYSHTAC2.423.643.622.68
Janssen–Cilag2.863.414.033.07
Celgene2.433.283.35
Incremental cost vs MP (£)SHTAC11,15935,7298544
Janssen–Cilag488812,2422234
Celgene19,76841,251
Incremental QALY vs MPSHTAC1.221.200.26
Janssen–Cilag0.551.170.21
Celgene0.850.92
ICER vs MP (£ per QALY)SHTAC913529,82033,031
Janssen–Cilag891210,49810,905
Celgene23,38145,024a
a

The value of £45,024 was not presented in the MS but has been calculated by SHTAC to allow comparison with outputs from the SHTAC and Janssen–Cilag models.

The value of £45,024 was not presented in the MS but has been calculated by SHTAC to allow comparison with outputs from the SHTAC and Janssen–Cilag models.

From: 7, Discussion

Cover of The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation
The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.41.
Picot J, Cooper K, Bryant J, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.